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1. Introduction 
Data from epidemiological studies indicate global increase in the incidence and prevalence of 
numerous autoimmune diseases (AD) as seen in the United States (Jacobson et al.1997). 
According to estimate from the US National Institute of Health (NIH) the prevalence of AD is 
in the range of 23.5 billion. From 1996 to date at least 237,203 cases per year of AD are 
diagnosed in the US; and of this, 42,137 are new cases of primary glomerulonephritis, multiple 
sclerosis, polymyositis/dermatomyositis and systemic lupus erythematosus (SLE). Early in 
1996 alone 6,722,573 women and 1,789,273 men suffered from varieties of diseases that had 
components of autoimmunity. Currently up to 150 autoimmune based diseases have been 
identified and approximately 40 more are awaiting confirmation. Similarly the incidence of 
several autoallergic diseases, type 1 insulin dependent diabetes mellitus (IDDM), rheumatoid 
arthritis, and Graves’ disease, hyperthyroidism included are on the increase. Of the 1.2 million 
new cases of AD diagnosed every 5 years, at least one or more cases will include these 
autoimmune disease components. (Jacobson et al.1997) 
The global incidence and prevalence for each AD is currently lacking and that calls for 
improvement on data collection and reporting. Nearly 10% of developed world’s population 
suffer from AD and contribute significantly to chronic diseases and mortality. Women are 
three times more likely to be at risk than men in acquiring these diseases with non-Caucasians 
at higher risk. We are also seeing global prevalence of allergic respiratory diseases on the 
increase for the past 20-30 years. Over 15 million people in US suffer from asthma alone; 
approximately 50 million are diagnosed with some form of allergic diseases (Smith et al, 1997). 
Presently the direct annual health care cost for AD in US is in excess of $100 billion US dollars 
as compared to $57 billion for cancer. Hospitalization alone takes over half the cost of the 
direct expenditures. Almost 20% of the population classified as ‘high-cost patients’ consume 
more than 80% of the resources. Consequently the cost to public health from clinical 
management of these conditions is on the increase. All indications point to future better 
www.intechopen.com
 Autoimmune Disorders – Pathogenetic Aspects 
 
4 
management of asthmatics through research and interventional efforts directed at 
communities, hospitalizations and high-cost patients in order to decrease health care resource 
use and provide cost savings. This calls for rigorous investigations into the role of 
environmental xenobiotics/substances and/or pollutants that are risk factors in the 
development of autoimmune diseases. In this chapter we intend to survey the public health 
concerns imposed by pollutants of the air, water and the food chain with concentration on 
typical examples of the effects of mercury on health to demonstrate the likelihood of dangers 
imposed through environmental and genetic disturbances in health. 
2. Environmental chemicals and autoimmune diseases 
Many scientists concur that several species within mammals to amphibians, birds, reptiles, and 
fish so far under monitoring systems are close to total extinction; well over 30,000 plant and 
animal species are estimated to be lost each year, a morbidity rate generally agreed to be much 
faster than at any time. Loss of species seems to be explained in most cases through the global 
weather changes as well as pollutional activities of man. But industrial activities seem to play 
major role in this problem; the latest data emanating from the industrial front estimate that at 
least 85,000 possible pollutants are currently being released into the environment through 
industrial activities alone http://www.epa.gov/glnpo/lmmb/substs.html (FDA/EPA).  
2.1 Chemicals and substances of public health concern 
These pollutants cover the heavy metals like thallium, aluminium, cadmium, lead, gold and 
mercury as well as pesticides, herbicides, preservatives, dyes, plastics, bisphenol A and rubber 
products. The Environmental Working Group indicated from studies in 2005 that a cocktail of 
287 pollutants are measured in new born US fetal cord blood (http://www.ewg.org/ 
reports/bodyburden2/execsumm.php). Perfluorooctanoic acid (PFOA or C8), and 
perfluorooctanoate, a synthetic but stable perfluorinated carboxylic acid and fluorosurfactant 
PFOA’s were included in the findings as well as pesticides, dioxins, flame retardants. Recently 
another concern has been brought to the limelight by the internal Florida Department of 
Environmental Protection (DEP) Workgroup. It is stated that the current update of the 
American Chemical Society’s Abstract Service reveals that as of August 2007 over 98% of the 
commercially available compounds are not under regulatory practices as they should be. This 
amounts to about 15 million out of over 32 million substances commonly referred to as 
Emerging Substances of Concern, or ESOC that have been registered for regulation (Chemical 
Abstract Service [CAS] website): http://www.cas.org/cgi-bin/cas/regreport.pl. 
Much uncertainty surrounds the outcome from releases of these substances into the 
environment. No information about the pharmacokinetics or pharmacodynamics 
interactions among life forms on these substances are available. No available information on 
transport and toxicological effects are on record. Within two years between 2005 and 2007 
over 5 million new chemicals have been reported to be registered and 5 million more 
chemicals became commercially available. Currently CAS informs that within each week 
more than 50 new substances or additions to existing substances to the database is the norm; 
http://www.cas.org/index.html. Apparently the ratio of unregulated to regulated 
chemicals keeps growing exponentially. The ESOC chemicals fall under various categories 
of organic groups encompassing from flame retardants (PBDEs), pharmaceuticals to 
endocrine-modulating chemicals (EMCs), nanoparticles to biological metabolites as well as 
newly discovered Industrial chemicals and toxins. They are constantly being discharged into 
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the environment where they find their way into our water bodies posing an unknown level 
of risk to life forms including humans, animals, and plants.  
Regulatory Agencies are therefore challenged to find answers to solve what may be an 
unknown outcome of these ESOC substances being continually released into the biosphere. 
In the absence of detail knowledge on the environmental outcome and without effective 
regulation no useful assessment can be made on the environmental risk posed. Thus vast 
majority of ESOC substances have to be non-traditionally managed by other means such as 
prevention and effects-based environmental assessment methods. That effort is even more 
tasking and presents difficulties in monitoring the trends of the etiology of diseases now 
becoming prevalent in the environment under such practices. ESOC substances are now 
recognized to be of global concern; among these are included polybromina -teddiphenyl 
ethers (PBDEs), perfluorooctanoic acid (PFOA), siloxanes, perfluorooctanesulfonate (PFOS) 
and hexa- bromocyclododecanes (HBCDs). PBDEs and HBCDs come under flame-retardant 
chemicals that are moderately long-lived and volatile; readily released to the atmosphere 
because they do not strongly bind to substrates. Once in the atmosphere they are globally 
transported and readily bioaccumulate in biological tissues.  
2.1.1 Nanoparticles  
Human activities now have added sources of environmental contaminants. Human-
originated nanomaterials are naturally man-made structures that differ in size range from 1 
to 100 nanometers (nm). They are commonly used in drug delivery nanotherapeutic 
pharmaceuticals, cosmetics, personal care products, energy storage products, fabrics, 
lubricants and equipments like golf balls. The use of nanomaterials has been on the increase 
and now it is ubiquitous. Their minuscule sizes allow traversing not only biological 
membranes but also the blood/brain barrier (BBB) and display physical and chemical 
properties different from parental compounds. Examples are gold or silver metals known to 
be inducers of autoimmunity but also possess magnetic properties. 
The intrinsic stereospecificity of these substances allow these molecules to play significant 
toxicological role in the environment (Donaldson et al 2004) and are therefore of public 
health concern. Carbon black displays enhanced severe effect than titanium dioxide 
(Renwick et al 2004), while the nanoparticle sizes of both chemicals are inducers of increased 
lung inflammation and destruction of the epithelial linings than their larger size. 
Adsorptions onto the surface of nanoparticles may play synergistic role in the reactivity; in 
vitro studies with fractions of diesel exhaust particles showed effects on cells (Xia et al 2004). 
Atmospheric nanoparticles may be complex enough to form interactions with organics and 
metals capable of higher levels of toxicity; metallic iron potentiates the effect of carbon black 
nanoparticles resulting in enhanced reactivity displayed as oxidative stress (Wilson et al 
2002). Conversely other combinations with pullulan (polysaccharide polymer of maltotriose 
units, also known as ǂ-1,4- ;ǂ-1,6-glucan) and dextran tend to reduce toxicity of the 
respective nanoparticles (Gupta and Gupta 2005, Berry et al 2003). 
Some nanoscale materials may be catalytic or behave as semiconductors, properties that can 
only increase the likelihood that nanomaterial could produce unanticipated toxicological 
effects. Nonbiodegradable ceramics, metals and metal oxides within nanomaterials are quite 
environmentally stable and persistent (EPA, 2007) and therefore undergo bioaccumulation 
in the food chain (Biswas and Wu, 2005). They are currently implicated in the induction of 
acute and chronic biological toxicity (Oberdörster, 2004a and 2004b; Lovern and Klaper, 
2005; Lam et al., 2004; Shvedovaet al., 2005; Fortner et al., 2005) of unknown physiological 
mechanisms and hence consequences.  
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2.1.2 Particulate matter  
Nanoparticles compare with particle pollution or particulate matter (PM), a group of 
complex mixture of extremely small air-borne particles and liquid droplets in air 
suspensions. There are a number of components covering acids (nitrates and sulfates, 
organic chemicals, metals, soil or dust and sulfates, organic chemicals, metals, soil or dust or 
mold spores). Particles less than 10 micrometers in diameter (PM10) pose an even worse 
health concern because of their inhalation properties that allow for accumulation in the 
respiratory system; they are found in all types of combustion (motor vehicles, power plants, 
wood burning, etc.) and some industrial processes. Severe health risks are posed among fine 
particles less than 2.5 micrometers in diameter (PM2.5). Fine particles easily lodge and 
penetrate deeply into the bronchial tree and into the deepest alveolar areas of the lung upon 
inhalation. Coarse particles measuring between 2.5 and 10 micrometers are derived from 
crushing or grinding operations, and dust from paved or unpaved roads.   
Properties of PM link them to a variety of significant health problems starting from 
offensive asthma to early mortality of exposed patients who suffer from cardiac and 
bronchial diseases. Exposures to PM result in high rate of respiratory symptoms involving 
irritation of the airways, coughing, or difficulty breathing, decline in lung functions, 
aggravated asthma, and development of chronic bronchitis, irregular heartbeat and nonfatal 
heart attacks. Individuals with a variety of health issues particularly those with prior heart 
or lung diseases tend to suffer premature deaths on exposure to PM. Children and older 
adults are the most likely to be affected by particle pollution exposure but healthy 
individuals are found to experience temporary symptoms from exposure to elevated levels 
www.epa.gov/asthma; and plays esthetic role by significantly effecting visibility 
impairment in the nation’s cities and national parks. To protect public health and welfare, 
EPA has continually issued National Ambient Air Quality Standards (NAAQS) since 1971 
for six criteria pollutants among which are particulate matter and Sulfur Dioxide (SO2), 
Ozone (O3), Nitrogen Dioxide (NO2), Lead (Pb), and Carbon Monoxide (CO). The NAAQS 
from EPA has undergone revisions in 1987 and 1997 and again in September 2006 and it is 
helpful to familiarize oneself; there is an urgent need for studies to unravel the 
pharmacokinetics and pharmacodynamics of these particles to help disclose the role played 
in disease pathogenesis especially concerning the autoimmune state- asthma being one of 
the priorities.  
3. Autoimmune diseases: etiologies and mechanisms 
All indications show that tissue burdens of PBDE in life forms including humans are 
doubling in every two to five years. Human breast milk has been found to contain as much 
as 419 ng/g lipid weight of PBDE (Schecter et al., 2003). The question then arises whether 
these molecules contribute to what we measure in the increases in the incidence of ADs. 
These substances are known to interfere with the reproductive and developmental stages of 
mammals as well as in birds and invertebrates (McKernan et al., 2006, Wollenberger 2005); 
they are carcinogenic, endocrine-modulating, and have neurotoxicological effects 
(Birnbaum, 2005). Autoimmune diseases present a major affront to the health of Americans 
as well as of global concern. Vast arrays of diseases come under auto-allergic/–immunity; 
these cover maladies that may present as localized to be organ specific or systemically 
distributed to the extremities to involve all organ systems typically noted in systemic lupus 
erythematosus (SLE). In health the Immune System guards us against invasion of foreign 
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substances including harmful bacteria, viruses, and parasites quite well without any 
perturbation. At times, however this machinery loses control and begins to attack even the 
self itself. Hypersensitivity responses resulting from direct attack of body components by 
antibodies or immune cells instead of attacking foreign substances alone generally come 
under autoimmunity or autoallergic responses. Autoimmune state becomes apparent with 
rise of demonstrable presence of autoantibodies or complexes of these with body substances 
or the presence of cells, T lymphocytes that attack self-constituents. Minor and harmless 
autoimmune states exist in normal persons in general; it is part component of the defense 
system as envisaged by Jerne‘s hypothesis (<http://www.enotes.com/microbiology 
encyclopedia/). In the disease state, however, autoimmunity becomes defined when the 
benign state results rather in pathology; it sets in motion homeostatic deterioration. The 
process is dependent on both genetic influences and environmental triggers. 
For the past decades it has been conclusively demonstrated that alleles of the major 
histocompatibility complex (MHC) contribute to the susceptibility to autoimmunity but 
relatively recently there is an unparalleled discovery of novel genes in molecular pathways 
implicated in autoimmunity. Some of the variants identified clearly participate in the 
modulation of T-lymphocyte (T-cell) activation and do contribute to many different forms of 
human autoimmunity. Other genes tend to have restricted roles, with susceptibility 
apparently confined to one autoimmune condition or to a specific ethnic group. To gain 
insight into the initiation mechanisms of autoimmune diseases requires identification of the 
genetic determinants underlying disease pathogenesis and this implicates new biochemical 
pathways. The Autoimmune state may be either the direct originator of disease itself or arise 
as a secondary disease from perturbations from other chronic diseases. Direct autoimmune 
states are phenotypically demonstrated in patients that have antibodies in the active disease 
phase: examples are represented by idiopathic thrombocytopenia (ITP), Grave’s disease and 
myasthenia gravis, pemphigus vulgaris and bullous pemphigoid, diseases that can be 
transferred among species through antibody transfers. 
Disease transfer through T lymphocytes exchanges have not conclusively been demonstrated to 
lead to pathology but with the aid of cytokines may rather alleviate or exacerbate disease state. 
Indirect cause of autoimmunity has been defined by Rose and Bona, 1993 as when disease can 
be induced in an animal model. SLE is well represented by several genetically determined 
mouse models which, while not exactly clinical replica of the human disease do very closely 
replicate pathological and serological characteristics clinically seen to occur. Hashimoto's 
thyroiditis and multiple sclerosis can be reproduced by immunizing animals with an antigen 
analogous to the putative autoantigen of the human disease. Absence of direct and indirect 
evidence with markers describing the state of autoimmunity become circumstantial: positive 
family histories for disease, presence of certain MHC class II alleles are examples.  
Currently it takes a great effort to assess accurately the initiation levels of these diseases in 
humans; the very initiating factors are difficult to focus on and in which stage/s or area of the 
metabolic processes gets initially disturbed becomes challenging to screen and allow for 
therapeutic management. Majority of ADs such as multiple sclerosis (MS), insulin-dependent 
diabetes mellitus (IDDM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and 
thyroiditis one finds representative spectrum of autoimmune diseases that appear to have 
etiological background in dysregulated immune system. Enough supporting evidence exist to 
confirm the autoimmune nature of many of these disorders but still it is gravely challenging to 
decipher their precise etiology and/or the initiating factors. Of late a small fraction of the T 
cells, the regulatory T cells are among the focal area of studies and have become recognized as 
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particularly crucial for control of autoreactive immune responses. Normally the processing of 
a self antigen by the antigen presenting cells (APC) allow binding of processed antigenic 
fragments to the MHC molecules within the APC followed by display of these MHC-peptide 
complexes on APC’s membrane surface for presentation to the appropriate T cells; this 
eventually terminates in activation of antigen-specific T cells. These T cells are then capable of 
attacking the self tissues expressing that particular self antigen. The process is believed to be 
the critical steps in the initiation of anti-self T cell responses. 
Genome wide studies indicate that costimulatory signals examplified by CTLA4 or PD1 and 
the modulators of T-cell receptor signaling (LYP, encoded by PTPN22), somehow must be 
confirmatory key checkpoint for human autoimmunity as happens in the T-cell during the 
period of T-cell receptor training to eliminate self-antigen carrying T cells in the thymus. 
This notion of the crypticity of self antigenic determinants (Sercarz et al., 1993; Moudgil and 
Sercarz, 2005) takes strength from the premise that rely on potentially immunogenic regions 
(determinants/epitopes) within a self antigen that are processed and presented by the MHC 
molecule to T cells at different levels of immunogenecity. This means that certain ‘dominant 
self’ epitopes are well processed and presented, whereas others, the (cryptic or recessive 
self) (Sercarz et al., 1993) ones are poorly or never processed and presented. Thus this type 
of staging of determinants (dominance/crypticity) in turn plays a critical role in thymus 
gradation of the T cell repertoire: the T cells specific for dominant self epitopes are tolerized 
with ease while those purportly aimed at cryptic self epitopes evade tolerance induction and 
become part of the mature T cell repertoire (Gammon and Sercarz, 1989; Cibotti et al., 1992; 
Sinha et al., 2004). 
T cells that evade tolerance induction are capable of being activated in the periphery under 
certain stressful inflammatory circumstances such as occur during infection; this has the 
consequence of enhanced processing and presentation of once latent (cryptic) determinants 
(Lehmann et al., 1992; Lanzavecchia, 1995). These activated T cells at times are capable of 
escaping appropriate constraint from regulatory T cells and permitted to execute their 
effector function of initiating autoimmune damage. The unveiling of previously cryptic 
determinants leading to activation of self-reactive T cells that escaped tolerance induction 
during thymic selection, owing to the crypticity of self determinants is considered a primary 
cornerstone of a theory of autoimmunity (Moudgil and Sercarz, 2005). The idea of 
determinant hierarchy provides a vital link between the thymic selection of potentially 
autoreactive T cells and the subsequent activation of these T cells in the periphery under 
conditions that facilitate the revelation of previously cryptic determinants. Peripheral 
ongoing immune tolerance of the mature immune system also attracts attention as another 
source of autoimmune initiation. This idea is supported by variations seen in the 
expressions of “self-antigen” in the thymus (e.g., insulin in T1D); in this instance T-cells are 
selected for survival according to the affinity of their cell surface receptors for self-antigen. 
This may represent a major key step in the genesis of autoimmune disease. 
Other means of autoimmune genesis stem from APCs. These cells play crucial role in 
antigen processing and presentation to the T-helper (Th) cells. Dendritic cells for example 
are key cells in the initiation and perpetuation of immune responses. Highly polymorphic 
genes within the MHC, with links to autoimmune inductions, encode proteins to which 
antigens bind and presented directly to T-cells by APCs. Another source of autoimmune 
initiation focus on the cell surface marker CD4-positive Th cells; they are the conductors of 
the adaptive immune response and many genes with an established role in autoimmune 
disease have their expression in this cell type.  
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Autoimmune diseases present specific issues that need attention. Drugs used to manage 
known chronic and acute diseases are implicated in triggering and are therefore thought to 
be indirect causes of various autoimmune diseases following administration. Many of the 
prescription drugs commonly used for highly prevalent diseases come under this category: 
these inexhaustively include drugs like Alferon N, Allopurinol, Atenolol, Atorvastatin, 
captopril, Penicillin, Carbamazepine, chlorpromazine, Chlorthalidone, cimetidine, 
Ethosuximide, gold salts, griseofulvin, Hydralazine, Interleukins, Infergen, Interferons, 
Interferon Alfa, Hydrochlorothiazide, Intron A, Isoniazid, Levodopa, Lithium, Lovastatin, 
Mesantoin, Methimazole, Methyldopa, Methylsergide, Metoprolol, Minocycline, Minoxidil, 
Ophthalmic timolol, Nitrofurantoin, Oral contraceptives, Quinidine, Phenytoin, PegIntron, 
P-aminobenzoic, Penicillamine, Perphenazine, Trimethadione, Pravostatin, Phenylbutazone, 
Procainamide, Valproic acid, Propylthiouracil, Simvastatin, sulfasalazine, sulfonamides, 
streptomycin, Sulfonamide antimicrobials, Tetracyclines, Tiotropium Bromide inhaler and 
Tumor Necrosis factor. 
The concern here can well be summarized with the incidence and/or prevalence of asthma, 
one of the most common chronic diseases of childhood estimated to affect 6 million children. 
More than 22 million Americans are diagnosed with asthma, and approximately 50 million 
of individuals are diagnosed with some form of allergic diseases. Presently in US the annual 
direct health care cost for AD in general is in excess of $100 billion US dollars as compared 
to $57 billion for cancer. Hospitalization alone takes over half the cost of the direct 
expenditures. “High- cost patients” that form about 20% of the population spend more than 
80% of the resources. As a result, the cost to public health from clinical management of these 
conditions is on the increase.  
4. Global problems associated with asthma and COPD 
Epidemiological data following the natural history of asthma reveal that in 1999 mortality 
rates from the disease declined in comparison to previous years. This was followed by a surge 
in recent decades in asthma prevalence also in the United States and other Western countries; 
data suggest this trend may also be reaching a plateau. The general trend of global asthma 
incidence is rising worldwide but looking at US data we see increased morbidity and mortality 
from asthma from 1980s -1990s with plateau in the 1990s. This finding is the reverse of what 
was seen in the 1978-1980 where an increase in mortality due to asthma was measured: from 
1990-1999 mortality declined. Commencing from 1995 the rate of outpatient visits for asthma 
increased; whereas the rates of hospital admissions declined from 19.5 per 10,000 of the 
population in 1995 to 15.7 in 1998 attributed to enhanced rates of dispensed steroid 
prescriptions for inhaled medications. This finding has been interpreted as due to the 
improved treatment of asthma responsible for these favorable developments. 
The implication, if it holds supports explanations of certain changes in environmental 
chemicals releases. Recent increases in asthmatic conditions in the population may be linked 
to many causes the cardinal one being the amount and types of substances that are being 
released increasingly into the biosphere. Releases of substances most of which have an 
unknown effect and still others closely linked to inductions of asthmatic features in the ever 
increasing population with genetic predispositions present ominous threat to the very 
survival of several species including man himself.  
Exposures to environmental factors early on in childhood play significant role in the risk in 
developing asthma. Clinicians have known for quite a while that asthma is not a single 
disease. Risk to asthma stems from early environmental factors as well as the presence of 
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susceptibility genes; subsequent disease induction and progression from inflammation as 
well as response to therapeutic agents plays big roles in disease etiology. It is a typical 
consequence of environmentally induced autoallergic disease known to be heterogeneous 
(Asosingh et al 2007, Dompeling et al, 2000, Dweik et al, 2001, Kharitonov and Barnes, 2001, 
Weiss, 2002, Pascual and Peters 2005, Salvato, 2001, Wu et al, 2000) existing in many forms. 
The immunologic profile of the asthmatic airways presents as proliferation and activation of 
helper T lymphocytes (CD4+) of the subtype TH2 responsible for the allergic inflammation 
in atopic asthmatics. Upon stimulation these cells release a number of cytokines covering IL-
4, agent for IgE synthesis, IL-5, essential for eosinophils’ maturation, and IL-3 and 
granulocyte-macrophage colony-stimulating factor, GMCSF (Bolland and Ravetch 2000, 
Candore et al, 2002, Lang et al, 2010, Pollard et al 1997). 
In allergic as well as nonallergic individuals we observe populations of eosinophils in the 
airways with increased levels in asthmatics with allergies http://www. clevelandclinicmeded 
.com/ medical pubs/disease management/allergy/ bronchial-asthma/that have higher rates of 
asthmatic attacks. These cells serve as the source of mediators that exert damaging effects on the 
airways. Ultimately, mediators lead to degranulation of effector/proinflammatory cells in the 
airways that release other mediators and oxidants, a common final pathway that culminates in 
chronic injury and inflammation commonly seen in asthma. Chronicity of the asthmatic 
condition has been confirmed by several parameters. Low pH and high output of reactive 
oxygen and nitrogen species (ROS) during asthmatic exacerbations are specific biomarkers in 
expired air reflecting altered airway redox problems (Clynes et al, 1988, Comhair et al, 2000, De 
Raeve et al, 1997, Dweik et al 2001). Superoxide, hydrogen peroxide, and hydroxyl radicals are 
among ROS agents that are responsible for the inflammatory changes in the asthmatic airway 
(Candore et al 2002, Bolland and Ravetch 2000, Pollard et al, 1997). These ROS originate from 
the lungs of asthmatic patients induced by activated inflammatory cells (ie, eosinophils, alveolar 
macrophages, and neutrophils) (Holgate et al, 2000). 
Pathogenicity in asthma in particular is portrayed by overall interactions between neural 
mechanisms, inflammatory cell mediators such as leukotrienes and prostaglandins, and 
intrinsic abnormalities of the arachidonic acid pathway and smooth muscle; all these cells 
play significant roles in the initial as well as disease progression. Inflammation is the most 
likely etiological basis of airway hyperreactivity and variable airflow obstruction.  
Asthma usually persists into later childhood and adulthood from early childhood in the 
presence of the appropriate genetic background. Tolerance to allergens is a normal security 
that prevents such responses, but the specific immunological events that mediate tolerance 
in this setting are still under scrutiny. Despite the explosion of information about asthma, 
the nature of the basic pathogenesis has not been established. However, asthma clearly does 
not result from a single genetic abnormality, but is rather a complex multigenic disease with 
a strong environmental contribution. For example, asthmatic children and adults sensitive to 
inhalant allergens such as dust mites, mold spores, cat dander, etc portray such reactions 
right from childhood compared with adult-onset asthmatics. Local epithelial environment 
within the connective tissue is believed to be actively involved in regulation of events and 
the relation between the airway epithelium and the subepithelial mesenchyme is proposed 
to be a key determinant in the concept of airway remodeling (Davies et al, 2003; Weiss, 2002; 
Li and Wilson 1997, Pascual and Peters, 2005, Salvato 2001). Difficulties and/or problems 
underlying diagnosis and classification of these diseases are simply due to the fact that most 
of the ADs become apparent only at variable phases of several chronic stages of organic 
ailments. Some ADs present as auto allergies covering several fields of diseases: the 
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incidence of several of these diseases is also on the increase and covers type 1 insulin 
dependent diabetes mellitus (IDDM), rheumatoid arthritis, and Graves’ disease, 
hyperthyroidism included. There is scarcity of information on the global incidence and 
prevalence for each AD. Some autoimmune/allergic diseases (AD) can be seen in cases of 
chronic obstructive pulmonary diseases (COPD). As such the incidence of these disorders 
has not been well defined. However, sharp global increases in the prevalence have been 
observed in the United States. 
Etiological initiators of and pathogenesis of most ADs are obscure; they are presumed to be 
numerous with cigarette smoking a typical COPD-associated. Cigarette smoking is clearly 
the major risk factor for COPD but exposures to other noxious substances including dusts 
and chemicals found under occupational settings are known to contribute to the 
development of the disease (Pauwels et al, 2001).The attributable fraction contributing to 
COPD cases caused by occupational exposures is estimated to be in the range of less than 
15% to as high as 31% among those who never smoked (Hnizdo et al, 2004). We find that 
minority groups have been historically overexposed to hazardous industrial substances and 
are candidates with increased risk for work-related airflow obstruction putting them highly 
in the AD group as well; making it necessary to improve on data collection and reporting. 
Estimation shows, however that nearly 10% of developed world’s population suffer from 
AD and contribute significantly to chronic diseases and mortality. Women are three times 
more likely at risk than men in acquiring these diseases with non-Caucasians in the higher 
risk groups. The global prevalence of allergic respiratory diseases including COPD has been 
also on the increase for the past 20-30 years.  
5. Mercury as environmental inducer of autoimmunity  
Psychoneuroimmunological studies demonstrate in various ways that homeostatic 
regulation of the internal milieu links the soma with the neural pathways; stressors effects 
relate the two in bidirectional pathways. Current Naturopathic Medical view of diseases 
also links the involvement of the genes to autoimmune proneness. In this wise the authors 
concentrate on the metal mercury as a representative highly reactive toxic agent within the 
body as a means of gaining an insight into the problem of etiologies of autoimmune 
diseases. Mercury has a high affinity binding to sulfhydryl as well as to hydroxyl, carboxyl, 
and phosphoryl functional groups very commonly displayed on macromolecules, proteins 
and the genetic materials. It is widely distributed as an environmental and industrial 
pollutant. No known beneficial metabolomic effect is assigned to mercury in the physiology 
of humans, yet a 70 kg man is loaded with an equivalent of 13mg mercury (Pier, 1975) 
distributed in the skin, nails, hair, and kidneys. The net outcome of exposure to mercury is 
dose-dependent and at low concentrations mercury is the agent for the induction of several 
diseases that affect most systems of the body. 
The central nervous system (CNS), the brain and the kidneys suffer most where Mercury 
Induced Autoimmunity (MeIA) can be particularly threatening in onset and severe among 
especially non-Caucasians that manifest defined major histocompatibility complex (MHC) 
haplotypes. Several data confirm that mercury is also associated with polyclonal cell 
stimulation. Mercury Induced Autoimmunity (MeIA) engages helper T lymphocytes in the 
induction of disease process in responder animals (Jiang YG, Möller G 1995, Horwitz and 
Stohl, 1993; Puck JM, Sneller MC. 1997) and in humans (Liossis et al 1996). It is suggested there 
is a genetic basis for airway hyperresponsiveness with linkage to chromosomes 5q, 11q (Li and 
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Wilson1997) and 12q24 in Hispanic subgroups (Salvato 2001). While MeIA is well characterized 
into different arrays of disease susceptibility in animal studies (De Raeve et al 1997) and in 
humans (Holgate et al, 2000, Li and Wilson 1997,) the role of mercury in the pathogenesis of 
autoallergic/immune syndromes like asthma and SLE is not well characterized.  
Our Microarray data resulting from low doses (1-3 μg/mL) exposures of human cell lines to 
mercury indicate differential expressions of several genes located on many human 
chromosomes. Most genes affected were expressed more than twice the control level; several 
genes were also down-regulated with mercury treatment. We found close to a total of two 
hundred highly up-regulated genes with greater than a two-fold change difference (p ≤ 
0.002) in the lowest mercury concentration (1µg/mL); 12 genes were moderately over-
expressed with an increase of more than one fold (p ≤ 0.005); and a total of more than two 
thousand genes were down-regulated albeit most repressions were not statistically 
significant (p0.05) according to the Wilcoxon’s Signed Rank test. Only forty of these genes 
were down regulated to statistically significant levels at p≤0.05 according to the Welch’s 
ANOVA/- Welch’s test. Clear distinctions were seen in the gene expression profiles of the 
experimental versus controls. Affected genes distributed among almost all of human 
chromosomes with higher than normal effects on genes associated with chromosomes 1-10, 
12, 14-18, 20 (sex-determining region Y), 21 (splicing factor and ATP-binding), X (including 
BCL-co-repressor). Genes affected include potassium voltage-gated channel–subfamily H 
member 2 (KCNH2), stress responses, G-protein signal transduction, putative MAPK 
activating protein (PM20, PM21), ras homolog gene family, cytokine receptor activity and 
polymerase (DNA directed), regulatory subunit (50kDa), leptin receptor involved in 
hematopoietin/interferon-class (D200-domain), and thymidine kinase 2, mitochondrial TK2 
(HGNC) and related genes. Closely associated genes on a chromosome tend to be influenced 
for expression perhaps due to the availability of close and adjacent phosphorylation receptors 
found by bioinformatics tools.  
Identified genes of interest that were over- or under-expressed operate in several pathways 
including principally the immune and cell cycle (cyclin-dependent kinases) pathways, 
apoptosis, and cytokine expressions (Figs 1-3) as well as the TGF-beta and the GABA, 
NMDA receptor subtypes. We have since confirmed that mercury has significant effect on 
GABA receptors in microarray experimentations in murine cell lines (unpublished data). 
Our lab results reinforce the capability of mercury exerting significant influence in most 
metabolic processes probably generating ROS (Kavuru et al 1998; Lang 2000, 2006, 
Montuschi and Barnes 2002, Wu et al 2000) that participate in the degree of disease outcome 
of the autoallergic/asthmatic syndromes.  The auto allergic phase is the body’s adverse 
response to the onslaught resulting in signs and symptoms invariably difficult to 
definitively differentially diagnose early on in disease. Estimates from the National Institute 
of Health (NIH) data indicate that in US alone the prevalence of AD to be about 23.5 billion 
(Jacobson et al, 1997); in 1996 approximately 1 in 31(3.13%) or 8.5 million people were 
afflicted with one form or other of AD. Since then at least 237,203 cases of AD are diagnosed 
annually; of this 42,137 are new cases of primary glomerulonephritis, multiple sclerosis, 
polymyositis/ dermatomyositis and systemic lupus erythematosus (SLE). Of the total 
6,722,573 are women and 1,789,273 men suffering from varieties of diseases that had 
autoimmune components (Jacobson et al, 1997, Smith et al, 1997). Currently almost 100 types 
of AD have been identified and approximately 40 more autoimmune-based diseases are 
awaiting clarification and confirmation.  
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Fig. 1. Results: HepG2 Genes affected by Mercury exposure 
5.1 Mercury toxicity: evidence for autoimmunity and neural problems  
Mercury (Hg) has long been recognized as a neurotoxicant; however, many experiments 
with murine models have conclusively implicated this heavy metal as inducer of 
autoallergies as well as immunotoxicant. In particular Hg has consistently been shown to 
induce autoimmune disease in susceptible animals with phenotypic consequence of 
autoantibodies overproduction and pathophysiological signs of lupus-like diseases. This 
finding has been endorsed by epidemiological studies demonstrating links between 
occupational Hg exposure and lupus. Mercury rather may interact with triggering events, 
such as genetic predisposition, exposure to antigens, or infection, to exacerbate disease. Non 
mercury-susceptible mice that are exposed to mercury do succumb to mercury-induced 
autoimmune disease (MeIA) with very low doses and short term exposures of inorganic Hg 
(20-200 µg/kg) exacerbates disease and accelerates mortality in the graft versus host disease 
model of chronic lupus in C57Bl/6 x DBA/2 mice. 
Furthermore, low dose Hg exposure increases the severity and prevalence of experimental 
autoimmune myocarditis (induced by immunization with cardiac myosin peptide in 
adjuvant) in A/J mice. Immunosuppression as well as immuno-stimulatory signals results 
from exposure to the metal in many species humans and rodents included (Pollard et al., 
1999). MeIA is prominent among some genetically predisposed individuals that carry 
syntenic genes as haplotypes in linkage disequilibrium.  Some of these individuals are 
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Fig. 2. Results: HepG2 Genes affected by Mercury exposure 
genetically prone to develop spontaneous autoimmune diseases. The etiology and 
pathogenicity of these, mostly systenic, autoimmune states have been difficult to trace. 
Immunological findings support the notion that the origins of majority of these idiopathic 
autoimmune diseases can be traced to environmental contaminants of the biosphere with 
xenobiotic compounds like silver, gold and mercury strongly implicated. Exposure to low 
levels of mercury (<40μg/kg body weight) in susceptible persons may be unsafe; predisposed 
individuals develop all types of AD typically systemic lupus erythematosus (SLE). Evidence is 
derived not only from experiments of nature as happened in Miamata in Japan but also from 
many strains of inbred mice described below. These strains of animals do develop lupus-like 
disease that imitate closely a simplified version of human systemic lupus erythematous (SLE), 
with the production of autoantibodies and the subsequent development of immune-complex 
mediated glomerulonephritis (Theofilopoulos et al., 1985). 
The general consensus is that the dose of mercury, duration of exposure as well as the genetic 
background of the exposed animal (Hanley et al., 2002; Hultman et al., 1992, 1993; Jiang and 
Möller, 1995; Kono et al., 1998; Pollard et al., 2002) contributes to disease outcome. The H-2 
haplotype plays important role in the specificity of resulting autoantibody as well as 
susceptibility to immune complex generation; but there is a role for involvement of non-MHC 
genes in MeIA susceptibility also. Acute renal tubular lesions and immunosuppression follow 
exposure to large doses, whereas chronic administration of smaller doses of mercury  
leads to the development of SLE (Bariety et al., 1971; Kasturi et al., 1995; Roman-Franco 
et al., 1978). Mercury-induced autoimmunity shares the same pathogenicity and clinical 
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Fig. 3. Key for Both Figs 1 and 2 
manifestations seen in patients suffering from clinically diagnosed systemic lupus 
erythematosus (SLE) (Dubey et al., 1991; Hirsch et al., 1982; Mathieson et al., 1992); the 
symptomatology is also the same (Biancone et al., 1996; Jiang and Möller, 1995; Kono et al., 
1998) with very minor differences.  
In humans most of the genes participating in immunity are located on the major 
histocompatibility complex (MHC) on chromosome 6 with its equivalent on the H-2 region on 
chromosome 17 in mice. The complexity of the interactions leading to disease state are reflected 
in the arrays of disease manifestations. Various susceptibility modes are demonstrated by 
different combinations of gene haplotypes in different strains of animals.  BALB/c mice of H-2d 
haplotype are highly susceptible to MeIA phenotypically demonstrated as lymphoproliferation 
without accompanying immune-complex glomerulonephritis (ICGN) (Jiang and Möller, 1995). 
Mice with B10.D2 haplotype specificity are capable of lymphoproliferation but with less severe 
ICGN than BALB/c mice on exposure to mercury. The H-2d haplotype DBA/2 strain of mice is 
however, resistant to both lymphoproliferation and ICGN (Hultman et al., 1992; Jiang and 
Möller, 1995; Kono et al., 1998; Takeuchi et al., 1995). RT-1n rats are susceptible, whereas RT-11 
haplotypes are resistant (Eneström and Hultman, 1995; Sapin et al., 1984). An H-2s haplotype 
carrying A.SW mice and others show high susceptibility to Hg-induced autoantibodies, 
whereas C57BL/6 strains (H-2b) are less susceptible. DBA/2 mice strains bearing H-2d 
haplotypes are not responsive while H-2k–bearing mice show intermediate susceptibility 
(Dubey et al., 1991; Hultman et al., 1993; Jiang and Möller, 1995; Kono et al., 1998).  
Most SLE susceptibility loci have been mapped in New Zealand hybrid models; at least 12 of 
them are located outside the H-1, the murine major histocompatibility complex, H-2. Three 
regions commonly noted by linkage studies in New Zealand models are found on murine 
chromosomes 1, 4, and 7 (Drake 1995, Kono et al., 1994, Morel et al., 1994); these have 
equivalent syntenies in human loci (Duits et al., 1995; Moser et al., 1998; Salmon et al., 1996) 
that seem to be ethnically distinct (Duits et al., 1995: Salmon et al., 1996). Another region 
along both H-2 class II and TNF-_ gene polymorphisms have been described to act as H-2-
linked predisposing genetic elements for the development of SLE; a very strong evidence 
suggests the contribution of TNF- polymorphism that may be the modulator of the initial 
steps of disease development (The Wbw2 locus (telomeric to H-2)) which was not linked 
with autoantibody production might play a role in determining lupus susceptibility; this 
reaffirms the clustering of functionally related H-2 and non-H-2 genes in the H-2 region on 
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chromosome 17 to be active players in the induction of SLE, a typical example of AD usually 
quoted. Genetic variants do exist in autoimmune susceptibility that may be a basis for health 
disparity among races and forewarns that in dealing with xenobiotics like mercury, 
susceptibility among different racial groups may exhibit differences enough to be taken into 
account in therapeutic managements.  
It has been determined that mercury is immunologically processed uniquely in disease 
pathogenesis. The process involves the antinuclear autoantibody, (AnoA Abs) response 
directed against fibrillarin. The AnoA Abs response directed against fibrillarin is one of the 
most representative manifestations of MeIA that is linked to H-2s (Hanley et al., 2002; 
Hultman et al., 1992; Hultman et al., 1993; Pollard et al., 2002) and, more specifically, to the 
class II I-As molecule, by analysis of H-2 congenic mice (Pollard et al., 2002) and is described 
below. The discovery of potential SLE inducibility on mercury exposure in humans offers 
the opportunity for comparison with data from murine models of SLE. This means that 
identification of potential SLE susceptibility loci in humans offers the chance to compare 
data from murine models of SLE induced by xenobiotics such as mercury. 
Mercury-induced cell death (MeICD) is processed through proteolytic breakdown of fibrillarin, 
a 34kDa MWt macrophage degradable protein component of small nucleolarribonucleoprotein 
particles (snRNPs); the generation of a unique (19kDa) proteolytic fragment required no pre-
interaction between mercury and fibrillarin (Pollard et al, 1997, 2002). 
MeICD was associated with a novel protease transiently synthesized and that stimulate self-
reactivity quite differently from that elicited by full-length protein. Above all xenobiotic-
induced autoimmunity characterized by autoantibody responses against native self-Ag did not 
require pre-interaction between xenobiotic and Ag. The genetically restricted anti-fibrillarin 
autoantibody response of MeIA was not found directed against a fibrillarin-Hg complex as 
expected of MHC-dependent antigen processing although a metal-protein interaction 
occurred (Pollard et al., 1997, 2002). This finding endorses a longstanding belief that SLE-
prone patients could generate self-autoantibodies spontaneously even without any physical 
presence of observable inducers of auto-antigens. Cell demise through MeICD was found to 
be mediated through both nonapoptotic and apoptotic protease activities but the processing 
pathway of fibrillarin was different enough to suggest the action of different proteases 
(Casiano et al., 1996; Pollard et al., 1997, 2002). It was surmised that the cleavage patterns for 
a number of auto-antigens must differ between non-apoptosis (HgCl2, heat, ethanol) and 
apoptosis (anti-Fas) induced cell death (Casiola-Rosen et al., 1995; Pollard et al., 1997). 
Apparently an MHC-restricted autoantibody response and interaction with HgCl2 are 
characteristics that differentiate fibrillarin as an autoantigen in HgCl2-induced 
autoimmunity. The observation that specific cleavage fragments of fibrillarin result from 
HgCl2 induced death and not other forms of cell death means that novel cleavage fragments 
probably act as autoimmunogens. Besides other effects of mercury on the immune system 
including specific cytokine requirements (Gillespie et al., 1995; Ochel et al., 1991; Van Vliet 
et al., 1993), inhibition of Fas-mediated cell death are possible means of terminating self-
tolerance leading to the equivalent of the SLE state (Whitekus et al., 1999).   
As detected in Asthmatic states MeIA is one of the autoimmune models in which TH1/TH2 
imbalance play critical roles (Biancone et al., 1996; Dubey et al., 1991; Hirsch et al., 1982; 
Jiang and Möller, 1995; Mirtcheva et al., 1989; Sapin et al., 1984). Although the mechanism 
by which mercury modifies the immune system is obscure, cationic mercury has a high 
affinity for sulfhydryl groups as the principal site for binding and also has a substantial 
affinity for amines, phosphoryl, carboxyl, and hydroxyl groups (ATSDR, 1999). Mercury is 
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capable of linking with macromolecules including the genetic materials and proteins to form 
complexes that can activate the immune system. Some of the modified proteins may have 
epitopes closely resembling self-immunogens (cryptic antigens) easily leading to 
autoimmune disorders in predisposed individuals (Pollard et al., 1997, 2002; Takeuchi et al., 
1995). The activation of CD4+ and CD8+ T cells requires a prior induction of antigen 
presenting cells (APC) (Jiang and Möller, 1995). Mercury binds to molecules on accessory 
APC cells and transforms molecules on these cells to superantigens capable of activating T 
cells with a particular set of Vǃ Ag-binding receptors (Jiang and Möller, 1995). The 
mechanism of MeIA can therefore be differentiated from mechanisms induced by polyclonal 
cell-activators (PCA) such as pokeweed mitogen, PWM. These PCA do not require helper T 
cells assistance in antibody/cellular inductions. 
The presence or absence of IFN-Ǆ on the responder or the non-responder TH1/TH2 cell types 
respectively is thought to be prerequisite in the response to or failure of response respectively 
(Kono et al., 1998). The balance between the TH1/TH2-type responses does not contribute 
directly to autoimmune susceptibility. Rather IFN-Ǆ has been found to be necessary for the 
activation of the immune system to respond to poor epitopes, including both self and non-self 
Ags leading to humoral and cellular auto responses. Dose differentials of IFN-Ǆ appear to 
directly contribute to disease proneness. High dose immunization with Ag and a strong 
adjuvant tend to override the IFN-Ǆ requirement (Ferber et al., 1996; Jones et al., 1997). 
Similarly, a strong genetic predisposition may decrease the threshold for susceptibility enough 
to overcome the IFN-Ǆ requirement (Abbas et al., 1996). Susceptibility to autoimmune diseases 
therefore is generally considered a multi-process with many stages or focal barriers evidenced 
by clinical observations in SLE patients (Andre et al., 1996; Hultgren et al., 1996; Manoury-
Schwartz et al., 1997; Vermeire et al., 1997). Lupus is therefore not inherited as a simple 
Mendelian trait but inherited as a multifactorial and complex trait. 
Latest information confirms that the steps to disease state are characterized by unknown, 
but a large number of susceptibility alleles that give rise to quantitative phenotypic effects. 
Dose effect allows each of the susceptibility alleles to have partial contribution to probability 
of increased disease severity. Still nongenetic factors do contribute to disease susceptibility. 
Recent linkage analyses have revealed over 100 large genomic regions, each represented as a 
quantitative trait locus (QTL)http://www.discoverymedicine.com/tag/quantitative-trait-
locus/ that are associated with increased susceptibility to lupus in mice (Kono et al., 2006) 
and at least 8 validated QTLs in families of lupus patients (Tsao, 2003) that partially overlap 
with the mouse QTLs. Some of the genes contribute to the murine lupus QTLs and 
participate in human SLE. Analysis of these genes is providing insight into pathogenesis of 
human SLE. Use has been made of linkage analyses on some model murine species that 
spontaneously get the lupus; these have involved analyses using 129, MRL-Faslpr, BXSB.Yaa, 
and the F1 hybrid between NZB and NZW (BWF1) and their recombinant inbred 
derivatives, NZM2410 and NZM2328.  
Statistically significant associations between over 100 genomic regions and a lupus-related 
phenotype covering most commonly lupus nephritis or anti-nuclear autoantibody (ANA) 
synthesis have been analyzed. Through substitution techniques whereby for example a QTL 
located in a lupus susceptible strain was replaced with the corresponding genomic interval 
from a resistant strain only 35 of the 100 genomic regions have been so far confirmed (Morel, 
2010). Substitution of the Adnz1 region (in NZM.C57Lc4 congenic strain) in lupus-prone 
NZM2328 mice with the appropriate genomic interval from a non-autoimmune genome led to 
the predicted and expected milder form of glomerulonephritis (Waters et al., 2004). Conversely 
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when the susceptible QTL was bred into a non-autoimmune genome such as B6.NZM2410.Sle1 
mice, which carry the NZM2410-derivedSle1 QTL that showed the strongest association with 
lupus nephritis, produced the expected high levels of ANA (Mohan et al., 1998). The 
implication was that none of the susceptibility loci was sufficient for the induction of full-
blown lupus pathology; each of these loci directed the expression of typical phenotypes such 
as ANA or increased lymphocyte activation (Morel et al., 1997). Therefore each of these 
component phenotypes itself has an independent genetic basis, at least in the mouse. 
In human SLE, risk haplotypes of some of the susceptibility genes such as STAT4 
(Sigurdsson et al., 2008) or IRF7/PHRF1 (Salloum et al., 2010) correspond to production of 
specific autoantibody profiles, suggesting that, as in mice, component phenotypes have 
unique genetic basis also. Confounders make the human analyses harder and difficult to 
explore due to the unavoidable co-expressivity of all other susceptibility alleles. Intersections 
of gene-function properties have been identified among the 35 validated murine susceptibility 
loci. High overlaps have been detected on chromosomes 1, 4, 7, and 13; longer areas are seen 
on chromosome 1; where 16 independent loci have been identified in 6 strains. The overlap is 
very conspicuous in the telomeric portion of chromosome 1 with its equivalent region 
localized in the human 1q23-42 site, a region identified to have many known linkages to 
human SLE (Tsao, 2003). These results tend to imply that at least some lupus-prone genes are 
shared among lupus-prone mouse strains and humans as well in that region. 
Characterization of the original QTLs lupus congenic strains corresponded to a cluster of 
susceptibility loci best demonstrated for Sle1: this corresponds to at least 7 independent loci. 
Phenotypic expressions of Sle1, ANA synthesis have been linked with 3 independent sub-
loci, Sle1a, Sle1b, and Sle1c (Morel et al., 2001). Further studies demonstrated that ANA 
production was feasible by the way of various distinct paths in each of these 3 sub loci. Sle1a 
regulates inducement of activated, nucleosome-reactive CD4+ T cells and inhibits the 
number of CD4+ Foxp3+ http://www.discoverymedicine.com/tag/foxp3/regulatory T cells 
(Chen et al., 2005a; Cuda et al., 2007) with contribution from two independent sub-loci 
within Sle1a, Sle1a1 and Sle1a2 (Cuda et al., 2010). Findings indicate Sle1b function to 
regulate tolerance in immature B cells (Kumar et al., 2006; Wandstrat et al., 2004). Sle1c, with 
its two subloci, Sle1c1 affects germinal center B-cell responses, and Sle1c2, that induces 
appearance of autoreactive CD4+ T cells respectively (Boackle et al., 2001; Chen et al., 2005b). 
Sle1d, sandwiched betweenSle1b and Sle1c2, enhances the severity of glomerulonephritis 
when mice carrying this allele are crossed with NZW mice (Morel et al., 2001). Also 
interlocked between Sle1a and Sle1b is the Fcgr2b the presence of which reduces expression 
on germinal-center B cells and plasma cells (Rahman et al., 2007): a phenotype known to 
have links with lupus patients (Mackay et al., 2006). The obvious deduction is that other 
lupus-prone strains may express identical state of genetic complexity in that region and at 
other loci and therefore is an avenue of either common or strain-specific genes, possible 
determinant of individual gene level and hence probable disparity among races. 
Synergistic interactions between specific loci were also found to be linked with co-expressivity 
found in Sle1 and Yaa on a B6 background that led to severe lupus nephritis (Croker et al., 
2003); the co-expression of either Sle2 or Sle3 with Yaa achieved only the phenotypes of either 
parent strains. In humans genetic interactions have been harder to identify for SLE (Harley et 
al., 2009) partly due to the extreme genetic diversity co-segregating with any gene or locus of 
interest. Additive effects have, however, been identified between risk variants ofSTAT4 and 
IRF5 (Abelson et al., 2009; Sigurdsson et al., 2008), suggestive of specific genetic interactions in 
human SLE. The co-expression of Sle1, Sle2, and Sle3 on a B6 background has been seen to give 
rise to fully penetrant lupus nephritis (Morel et al., 2000).  
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A clear demonstration of mercury’s possible influence on several metabolic pathways is 
seen in the number of possible pathways affected Figures 1-3: red coloration indicates 
upregulated genes and blue coloration indicates inhibition of gene expression on exposure 
to mercury. Mercury exposure leads to effects on several of biochemical pathways involving 
products of genes in cell cycle signaling: G2/M checkpoint regulation, TGF-ǃ, IGF-1, insulin 
receptor activity, chemokine, Wint/ ǃ-catenin, integrin, PPAR, SAPK/JNK, JAK/Stat, B and 
T cell receptor, G-protein-coupled receptor, IL-2, ERK/MAPK, death receptor signaling such 
as apoptosis, NF-κB, cell cycle and above all immune responses regulated by most of these 
genes. Pathways indicated are examples of mercury’s potential to affect susceptible 
individuals that carry MHC haplotype combinations and who are prone to develop not only 
autoimmune and/or cancerous diseases but risk factors for obesity and other chronic 
associated diseases yet to be evaluated through mercury toxicity. 
Our studies confirm that several genes in haplotype combinations are subjected to pronounced 
changes on exposure to environmental mercury. Among these genes we mention the 
transforming factor beta (TGF-ǃ) superfamily of cytokines. This group of family genes is 
associated with regulating the cell cycle essentially for maintenance of normal immunological 
homeostasis and lymphocyte proliferation. Proteins synthesized from these genes play 
important roles in regulating essential cellular functions such as differentiation and apoptosis. 
TGF-ǃ superfamily of cytokines is over expressed on mercury exposure. Some cells, 
lymphocytes among them are known to respond to TGF-ǃ by undergoing apoptosis. 
Apoptosis may lead up to accumulation of self-antigens within a localized part of the body 
and break the body’s immunological tolerance to give rise to the autoimmune state. The 
mechanisms regulating this process are yet to be clarified. Over expression of TGF-ǃ cytokines 
induced by mercury may lead to transcription of Smad6 and Smad7; these molecules act as 
inhibitors of TG  apoptosis is necessary for maintenance of tolerance. Failure to eliminate 
immature B cells has the consequence of autoimmune diseases and cancer development. 
Several aberrant functions associated with many pathways involving the cell cycle and the 
immune responses are therefore possible through intoxication with mercury. Such wide effects 
of mercury translate to risk associations when disease susceptibility is our prime concern. This 
means that it is only at the right genetic combinations and the appropriate line-up of 
associated genes that disease susceptibility ensues. That goes to argue for severity of disease as 
well. Mercury-exposed individuals carrying the appropriate allelic-combinations located on 
specific haplotypes are prone to develop autoimmune diseases.  
Not only do some metals induce autoimmunity but can also affect the nervous system when 
present during fetal development. Mercury readily crosses the human placenta and 
accumulates in fetal tissue during gestation (David et al., 1972). Mercury can concentrate in 
umbilical cord blood significantly more than in the maternal blood (Sakamoto et al., 2004). 
This could affect various developmental processes (Clarkson, 1997; Hassett-Sipple et al., 
1997; Pendergrass et al., 1997) leading to behavioral dysfunctions associated with autism 
(Bernard et al., 2001) and others. Arrhythmias and cardiomyopathies have also been 
associated with mercury toxicity. Mercury intoxication can result in mental retardation, 
cerebral palsy, seizures and ultimately death (WHO, 1990). For the early protection of 
children, it becomes necessary to come up with reliable and relevant tools that identify 
chemicals with developmental neurotoxicity potential. Once identified, these neurotoxicants 
need to come under regulatory practices in order to restrict their use and to control exposure 
as, for example in the case of lead (Silbergeld, 1997).  
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5.2 Spontaneous lupus: who are at risk 
To date genetic mappings endorse genetic susceptibility to autoimmunity and confirms it to be 
highly associated with individuals with certain combinations of genes in MHC-haplotype 
linkages: Fasl (CD95/L), Sap (serum amyloid P-component), FcǄr2b (FcǄRIIB), Cr2 
(CD21/CD35) and Ptprc (CD45) amongst them. Deficiency in individuals of Fcer1g (FcRγ-
chain) results in resistance to autoimmunity. These genes are not by any means exhaustive. As 
mentioned above gene type and dosage seem to determine severity of autoimmune diseases. 
This indicates that susceptibility and/or initiation factors operate via multiple pathways 
subjected to regulatory or focal checkpoints that finally give rise to the pathological state. The 
situation is exemplified by SLE, type 1 diabetes, IDDM and RA patients. In genetically 
predisposed patients the synthesis of autoantibodies and/or the generation of cellular attack of 
self-antigens may follow different pathways. Such mechanisms are known to be influenced by 
gene dosage and contributions from ethnic and environmental background. Clinical 
management or treatment schedules need to vary accordingly.  
Thus lupus susceptibility genes are now of deep interest to immunologists/allergists and 
are being identified in the mouse and their contribution to the disease state is being actively 
sought through analysis of rare or common variants. Discoveries of the roles of the 
susceptible lupus genes mainly in the mouse have given insights and critical lead to links 
with human SLE disease patterns. However the molecular mechanisms by which they 
contribute to autoimmune pathogenesis are yet to be clearly defined. The multifactorial 
complex nature of lupus disease susceptibility is currently thought to operate via a 
combination of common genetic variants that result in small phenotypic effects; rare 
variants end in large phenotypic effects (Cirulli et al., 2010). So far identified common 
variants in lupus susceptibility genes include the PTPN22 or IRF5 among others. Genome 
wide Association studies (GWAS) and analysis also reveals scarce variants such as C4 and 
TREX (Graham et al., 2009). Rare SIAE variants responsible for the loss-of-function have 
been linked with autoreactive B cells (Surolia et al., 2010); the lpr and gld in humans 
represented in lupus-prone murine strains lead to a functional decline in CD95 or C95L, 
respectively (Cohen et al., 1992); the Yaa mutation, an equivalent of a Tlr7 gene duplication 
(Pisitkun et al., 2006), and a mutation in the Coronin A1 gene in the B6.Faslpr/Scr strain that 
regulates CD4+ T cell activation (Haraldsson et al., 2008) have all been located. 
The murine equivalent of humans common variant genes have now been identified for SLE. 
NZB and NZW allele of Fcgr2b encode a negative regulator of B-cell signaling and 
predicates an autoimmune phenotype (Rahman et al., 2007; Xiu et al., 2002). Studies 
currently endorse links between FCGR2B variants and human SLE (Lee et al., 2009). Cr2 
polymorphism that function to encode the complement receptor type 2, a B-cell co-receptor 
known to contribute to the Sle1c1 phenotypes (Boackle et al., 2001; Chen et al., 2005b). SLE 
patients do carry a common CR2 haplotype more frequently than in healthy controls; and 
follicular dendritic cells (FDC) express a novel CR2 splice variants of SLE patients (Douglas 
et al., 2009; Wu et al., 2007). Sle1b corresponds to polymorphisms in four signaling 
lymphocytic activation molecule (SLAM) family member genes (Wandstrat et al., 2004), 
including Ly108 directly implicated in the regulation of B-cell tolerance (Kumar et al., 2006). 
Variants of SLAMF3 (LY9) and SLAMF4 (CD244) have also been linked with human SLE 
(Graham et al., 2008; Suzuki et al., 2008). For the Sle1 sub-loci, Sle1a.1 corresponds to the 
expression of a novel splice isoform of the Pbx1 gene that is associated with increased CD4+ 
T cell activation in both mice and humans (Cuda et al.,2007, 2010). Searches are still going on 
to reveal the mechanisms linking Pbx1 expression and T cell phenotypes. Complex 
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phenotypic expressions are associated with Sle3 locus that includes myeloid cell-induced 
CD4+ T-cell activation (Zhu et al., 2005) and mild glomerulonephritis (Mohan et al., 1999). 
Kallikrein (Klk) polymorphic genes, serine esterases that regulate a wide spectrum of 
biological functions in the kidney including inflammation, apoptosis, redox balance, fibrosis, 
and local blood pressure located in the Sle3 interval have been linked with increased 
susceptibility to nephritis in SLE mice and SLE patients (Liu et al., 2009).  
To date close to 22 identified and validated loci with confirmed associations with SLE 
susceptibility (Graham et al., 2009) have been mentioned in the literature. These loci are 
placed in one of four groups on the basis of mouse characteristics (Morel, 2010). Group one 
genes are thought to be directly implicated in lupus pathogenesis through their capacity to 
either induce or modulate disease in the mouse. A representative one is STAT4, a 
transcription factor linked with signal transduction of the IL-12 and IL-23 receptors that has 
a critical role in regulating the effector functions of helper T cells (Korman et al., 2008). In 
addition, Stat4 deficiency modifies disease severity in the NZM lupus models (Jacob et al., 
2003; Xu et al., 2006). The IRF5 whose risk alleles are associated with an increased 
production of interferon alpha (IFNǂ) in SLE patients (Niewold et al., 2008) is a puzzling 
piece. In two different murine models (Richez et al., 2010; Savitsky et al., 2010) IRF5 
however, failed to establish a link between IRF5 and IFNǂ, pointing instead to a 
transcriptional control of the IgG2a locus. It is still not clarified if these discrepancies reflect 
species-specific functions of IRF5 or whether the association between IRF5 polymorphisms 
and IFNǂ production does not involve a direct mechanistic link between the two genes. The 
second group covers GWAS-identified SLE susceptibility genes with known functions in the 
murine immune system but without current established link with lupus pathogenesis in 
man. For example, tumor necrosis factor alpha-induced protein 3 (TNFAIP3) and its binding 
partner TNFAIP3-interacting protein 1 (TNIP1) are negative regulators of nuclear factor κB 
signaling and tumor necrosis factor (TNF)-mediated apoptosis (Vereecke et al., 2009). 
These findings imply that overexpression of TNFAIP3 would inhibit pathogenesis in lupus-
prone mice; its deficiency would exacerbate disease. Newly discovered genes without a 
known function are placed in the third category of genes associated with SLE in GWAS. The 
JAZF1 in this group has now been associated with multiple human phenotypes (Gateva et 
al., 2009) still awaiting detailed basic functions workout. FCGR2A belongs to the fourth 
group of genes and is associated with SLE risk in GWAS but has no equivalent ancestral 
gene in the mouse, and therefore cannot yield information for human SLE analysis.  
6. Conclusions  
The Biosphere is gradually being overwhelmed with several substances from industrial and 
other activities that has direct role in changes in the incidence and prevalent measures in 
various diseases. Among these diseases the autoimmune state seems to be a major avenue 
that impacts and disrupts the homeostatic mechanisms. Autoimmune diseases like asthma 
are excellent representation of environmental problems acting as indicators of atmospheric 
as well as the air, the soil and water bodies that are affected by pollutional activities. Thus 
rises in the incidence and the prevalence of AD within the communities count as direct role 
of the environmental pollution affecting the gene pool and becomes public health concern. It 
is important to follow the effects of these substances and the pathways of disease 
pathogenesis. Currently GWAS is becoming a powerful tool or vehicle that is helping in the 
understanding the functional roles of the polymorphic alleles particularly those alleles 
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prevailing across ethnic groups. Analyses of population differences in autoimmune state is a 
first and important step in unraveling the complexity of these genes affected by 
environmental pollutants represented by mercury. It is common knowledge now that 
environmental contaminants through the food chains occur; pesticides are found in fruits, 
vegetables and cereals of European origin estimated to contain about 300 biocides in food 
products (Commission of the European Communities, 2007, Suñol, 2009), also seen in the 
urine in majority of US population (Mage et al., 2004); and human adipose tissue, serum, and 
placenta in agricultural areas (López-Espinosa et al., 2007). 
Studies in the laboratory reveal increasing concern as to whether pesticides currently used can 
cause neurodevelopmental toxicity (Bjorling-Poulsen et al., 2008). Similar concerns go for 
several substances released into the environment. Regulatory checks help to determine the role 
they play in diseases seen in the population. We are at a time that full-genome association 
analyses can produce equivocal array of data, some of which are likely to provide vital new 
biological insights into autoimmunity that may hold the key to novel therapies. The state of the 
matter is that susceptibility alleles of autoimmune diseases are now believed to fall into two 
general groups: (1) those genes that confer susceptibility to multiple autoimmune phenotypes 
(CTLA4, TPN22, PDCD1, FCRL3); and (2) those that confer tissue specificity to autoimmunity 
(INS in T1D, PADI4 in RA). Of note also is that allelic diversity within the MHC is also a major 
determinant of tissue specificity. Having a clear understanding of the genetic basis of 
autoimmunity and the application of this knowledge to appropriate clinical therapies may 
provide clinical social medicine benefits in several ways. It may be possible to have early 
diagnostic tools to detect high risk individuals at the highest genetic risk in prospective 
longitudinal studies aimed at defining the role of manageable/preventable environmental 
influences on disease. Also the identification of genetically susceptible individuals will enable 
targeting of preventive therapy once it becomes available at or evasion of detrimental 
environmental influences. It may also be helpful to align genetic profiles with prognosis as 
seen in degrees of disease severity in SLE, RA, IDDM etc or response to specific therapies so 
that more appropriate or aggressive treatments can be selectively targeted. This will 
particularly be of unimaginable use in health disparity studies.  
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